A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster

NCT05609045 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped business strategy adjustment

Conditions

COVID-19 Pandemic

Interventions

BIOLOGICAL: Lyophilized COVID-19 mRNA Vaccine
DRUG: Sodium chloride

Sponsor

Wuhan Rhegen Biotechnology Co., Ltd.

Collaborators

[object Object]
[object Object]